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Abstract
Background: Pseudohypoparathyroidism (PHP) indicates a group of heterogeneous disorders whose common feature is
represented by impaired signaling of hormones that activate Gsalpha, encoded by the imprinted GNAS gene. PHP-Ib
patients have isolated Parathormone (PTH) resistance and GNAS epigenetic defects while PHP-Ia cases present with
hormone resistance and characteristic features jointly termed as Albright’s Hereditary Osteodystrophy (AHO) due to
maternally inherited GNAS mutations or similar epigenetic defects as found for PHP-Ib. Pseudopseudohypoparathyroidism
(PPHP) patients with an AHO phenotype and no hormone resistance and progressive osseous heteroplasia (POH) cases have
inactivating paternally inherited GNAS mutations.
Methodology/Principal Findings: We here describe 17 subjects with an AHO-like phenotype that could be compatible with
having PPHP but none of them carried Gsalpha mutations. Functional platelet studies however showed an obvious Gs
hypofunction in the 13 patients that were available for testing. Methylation for the three differentially methylated GNAS
regions was quantified via the Sequenom EpiTYPER. Patients showed significant hypermethylation of the XL amplicon
compared to controls (3663 vs. 2963%; p,0.001); a pattern that is reversed to XL hypomethylation found in PHPIb.
Interestingly, XL hypermethylation was associated with reduced XLalphaS protein levels in the patients’ platelets.
Methylation for NESP and ExonA/B was significantly different for some but not all patients, though most patients have site-
specific CpG methylation abnormalities in these amplicons. Since some AHO features are present in other imprinting
disorders, the methylation of IGF2, H19, SNURF and GRB10 was quantified. Surprisingly, significant IGF2 hypermethylation
(20610 vs.1 4 67%; p,0.05) and SNURF hypomethylation (2366 vs.3 2 66%; p,0.001) was found in patients vs. controls,
while H19 and GRB10 methylation was normal.
Conclusion/Significance: In conclusion, this is the first report of methylation defects including GNAS in patients with an
AHO-like phenotype without endocrinological abnormalities. Additional studies are still needed to correlate the methylation
defect with the clinical phenotype.
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Introduction
Heterozygous inactivating mutations affecting the GNAS gene
have been reported to cause Albright’s Hereditary Osteodystrophy
(AHO, MIM 300800), a complex and broad phenotype mostly
characterized by short stature, obesity, round face, subcutaneous
calcifications, brachydactyly and cognitive impairment [1–4].
Patients carrying GNAS loss-of-function mutations on maternally
inherited alleles have pseudohypoparathyroidism type Ia (PHP-Ia,
MIM 103580) that is characterized by AHO and resistance to
multiple stimulatory G protein-coupled hormones (e.g. Parathor-
mone (PTH) and others) [5–10], while patients with paternally
inherited GNAS mutations are reported as having only AHO
features or pseudopseudohypoparathyroidism (PPHP) (Table 1)
[2,4,11,12]. Progressive Osseous Heteroplasia (POH, MIM
166350) describes a severe disease characterized by ectopic bone
formation that affects not only the subcutis, but also the skeletal
muscle and the deep connective tissue. POH is considered as an
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38579extreme variant of PPHP that can be associated with some AHO
features and is also caused by paternally inherited GNAS
inactivating mutations (Table 1) [13]. GNAS imprinting defects
have extensively been described in pseudohypoparathyroidism
type Ib (PHP-Ib, MIM 623233) patients [11,14] with hormone
resistance to PTH and TSH only and having no AHO. However,
recent studies have shown the presence of epigenetic GNAS defects
in PHP-Ia patients without mutations in the GNAS coding region
(Table 1) [15–19]. These findings suggest a reclassification of
PHP-Ia and PHP-Ib patients as extreme ends of one heteroge-
neous group of GNAS (epi)genetic defects. The latter is further
supported by the Gs functional overlapping between PHP-Ia and
PHP-Ib recently reported, where Gsalpha hypofunction, deter-
mined either in isolated erythrocyte membranes or in platelets, has
been detected also in patients with GNAS imprinting mutations,
AHO features and hormone resistance [15,20,21]. Gsalpha loss of
function is also a finding in PPHP patients [20,22,23]. However,
despite the fact that large-scale studies showed an association
between AHO phenotype and loss of Gs activity [22,24–26], only
a small number of PPHP subjects have inactivating GNAS
mutations. The severity of the AHO phenotype varies greatly
between patients, and some patients have only few features of the
syndrome.
Some clinical characteristics of AHO are also reported in
imprinting syndromes Silver-Russell, Beckwith-Wiedemann, Pra-
der-Willi and Angelman that are mainly characterized by defects
in growth, behaviour and/or development. To further support the
common soil of imprinting disorders, an ‘imprinting gene network’
that regulates embryonic growth and differentiation dependent on
Zac-1 (also known as pleiomorphic adenoma gene-like 1
(PLAGL1)) regulation has been identified [27]. A subset of
imprinting genes has been found to influence growth progression
via coordination of the glucose-regulated metabolism [28]. Among
those genes, together with GNAS also the IGF2/H19 cluster and
the SNURF/SNRPN regions have been described to play a
causative role in embryonic growth defects. DNA methylation
defects involving imprinting control region 1 (ICR1) of the IGF2/
H19 locus for which methylation abnormalities result in two
growth disorders with opposite phenotypes: the overgrowth
disorder Beckwith-Wiedemann syndrome [29] with maternal
H19-ICR1 hypermethylation and the growth retardation disorder
Silver–Russell syndrome [30] with paternal H19-ICR1 loss of
methylation. Prader-Willi and Angelman syndromes [31] are
distinct neurodevelomental disorders that are associated with the
deletion of the chromosomal 15q11–13 region, loss of imprinting
or uniparental disomy of chromosome 15. The SNURF/SNRPN
region is hypermethylated in some Prader-Willi syndrome patients
[31].
We here study the methylation of the growth regulatory
imprinted genes GNAS (NESP, XL and ExonA/B amplicons),
IGF2/H19 and SNURF in 17 patients with some typical AHO
features that mainly include in common growth retardation and
brachydactyly. Methylation studies of GRB10 are also performed,
as the imprinting of this gene is not actually linked to growth
regulation but rather to behaviour [32]. All 13 patients that were
available for platelet Gs testing showed a significant platelet Gs
hypofunction but they did not carry GNAS coding mutations.
Materials and Methods
Ethics Statement
Verbal informed consent to collect blood samples for advanced
non-routine diagnostic procedures was obtained from the partic-
ipants and/or their legal representatives. This strategy is in
agreement with the Belgian Law and local regulations and was
specifically approved for this study by the Ethics Committee of the
Katholieke Universiteit Leuven- University of Leuven. The Ethics
Committee of the Katholieke Universiteit Leuven- University of
Leuven, also waived the need for formal approval by the ethical
review board.
Participants
Patients enrolled in this study were followed at or referred to the
pediatric endocrinology department of the University Hospital in
Leuven (Belgium).
Patients were selected based on having AHO features, mostly
with severe short stature, mental retardation or behavioural
problems, clinodactyly or short metacarpals. Few patients also
showed obesity and none of them presented with subcutaneous
calcifications. One patient (patient 5) showed heterotopic ossifica-
tions, and was diagnosed with Progressive Osseous Heteroplasia
[33,34]. Other clinical characteristics were also present and are
reported in Table 2. None of the patients had abnormal PTH,
calcium or phosphate values.
Functional platelet Gs pathway test
The platelet aggregation-inhibition test was performed as
described [35–38]. Samples were processed within 3 hours after
blood drawing. Different concentrations of a Gs agonist being
prostaglandin E1 (PGE1, ProstinH;0 21 mg/ml; Pfizer Inc., NY,
USA) or the stable prostacyclin analogue Iloprost (IlomedineH
025 ng/ml; Bayer Schering Pharma AG, Berlin, Germany) were
added one minute prior to induction of aggregation with collagen
(2 mg/ml). The 50% inhibitory concentration (IC50) was evaluated
for each Gs agonist from the patient’s response curve and
compared to the mean IC50 measured on platelets of a group of
controls (n=24) for the same agonist [20].
Table 1. Phenotypic, Molecular Genetic and Platelet Gs protein activity in relation to GNAS pathology.
PHP-Ib PHP-Ia PPHP POH
AHO features no yes yes rarely
PTH resistance yes yes no no
Heterotopic ossification no no no yes
GNAS defect Epigenetic GNAS defects Mutations in exons 1-13/
Epigenetic GNAS defects
Mutations in exons 1-13 Mutations in exons 1–13
Platelet Gsa activity
20 Mildly reduced reduced reduced /
Transmission maternal maternal paternal paternal
doi:10.1371/journal.pone.0038579.t001
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DNA was extracted from leukocytes from all patients. Exons 1
to 13 of GNAS were amplified and sequenced using conditions
previously described [20]. The presence of STX16 deletions was
investigated as described [20,39–41]. To rule out the presence of
other deletions in the upstream GNAS region, we performed
genotyping of different SNPs by PCR and direct sequencing
within the NESP55, XL and Exon A/B regions (for overview of all
SNPs see Table S1).
GNAS, IGF2, H19, SNURF and GRB10 methylation analysis
Genomic DNA (1 ug) was used for bisulfite treatment with the
MethylDetector
TM bisulfite modification kit (Active Motif, Carls-
bad CA) as described [19].
NESP, XL, Exon A/B and SNURF methylation was studied via
Sequenom EpiTYPER technology using primers and conditions
already reported [19]. New amplicons to study IGF2, H19 (ICR1
region) and GRB10 regions were designed using the Sequenom
EpiDesigner software. Primers and amplicons characteristics are
reported in Tables 3 and 4. All PCR amplifications were
performed in triplicate. When the triplicate measurements had a
SD equal to or greater than 0.10, all data for the sample involved
were discarded (removing 8% of measurements). Sequenom peaks
with reference intensity above 2, overlapping and duplicate units
were excluded from the analysis.
The sequence and chromosomal location of all amplicons are
shown in Figures S1, S2, S3.
Genetic analysis of IGF2 and SNURF amplicons
To rule out the presence of SNPs that could interfere with the
methylation detection sensitivity in the IGF2 and SNURF
amplicons, we have screened for the presence of SNPs in the
same region that was used for the Sequenom analysis and its
surrounding region. A list of all the IGF2 and SNURF SNPs are
reported in Tables S2 and S3 that could exclude also deletions
in the loci as most patients are heterozygous for the intronic SNPs
rs734351 and rs2855523.
Platelet immunoblot analysis
Platelet immunoblot analysis for XLalphas, Gsalphas and CAP-
1 was performed as described [20] Platelets isolated from citrated
blood were directly lysed in ice-cold PBS containing 1% igepal
CA-630 (Sigma Chemical, St. Louis, MO), 2 mmol/liter Na3VO4,
1 mmol/liter EDTA, 1 mmol/liter phenylmethylsulfonyl fluoride,
2 mmol/liter dithioerythreitol, 1% aprotinin, and 2 mmol/liter
NaF, and incubated on ice for 60 min. Platelet extracts (50 mg)
were mixed with Laemmli sample buffer and resolved by SDS/
PAGE. Blots were revealed with a monoclonal anti-Gsa antibody
[42] a monoclonal anti-XLas antibody (11F7) [43] or a
monoclonal anti-CAP1 antibody as loading control (Santa Cruz
Biotechnology Inc.). Bands were quantified using the Java image
processing program ImageJ 1.34 g (NIH Image software).
Statistical analysis
Average of CpGs methylation for each amplicon was calculated
for both controls and patients samples. Statistical analysis was
performed using PRISM 5.0a software. Two-tailed unpaired T-
test (p,0.05) was used to study group methylation differences
between PPHP patients and healthy controls for all the imprinting
control regions studied and to evaluate protein expression
differences.
A more individual statistical approach was then performed
comparing each patient’s Sequenom CpG value or amplicon
average with the distribution of values of the same variable
measured in a group of healthy controls (n=41 for NESP, n=48
for XL and GRB10, n=47 for Exon A/B, n=45 for IGF2,n=3 3
for H19, n=35 for SNURF) (Z-test, P,0.05). Values with a Z-
score #22 and $+2 were considered significantly hypo- or
hypermethylated, respectively. Normality test was assessed with
SPSS 12.5 software to study the control population values
distribution.
Results
Platelet Gs function
We studied platelet Gs activity in 13 PPHP patients with
variable AHO features as reported in Table 2. For patients 1 to 4
Table 3. Primers used in the Sequenom study to amplify
IGF2, ICR1/H19 and GRB10 regions.
primer’s name nucleotide sequence
IGF2_F 59-aggaagagagGTTGGAGGGTTTTAAAGTGGGG-3
IGF2_R 59-cagtaatacgactcactatagggagaaggct
CAACTCAAATCCTACCTACATAA-39
H19_4_F 59-aggaagagagTAGTTTAAGTTTTTTTTGGATGGGG-39
H19_4_R 59-cagtaatacgactcactatagggagaaggct
AAAACAACAATAACACTCCCAACTC-39
H19_14_F 59-aggaagagagTTTGGTAGGTTTAAGAGTTTAGGGG-39
H19_14_R 59-cagtaatacgactcactatagggagaaggct
AAAACCCTACAAAAAAAATCTCACC-39
GRB10_F 59-aggaagagagGTTTAAATGGGATTTTATTTTGTTT-39
GRB10_R 59-cagtaatacgactcactatagggagaaggct
AATCCCTAATTCTCATAACAACCCT-39
doi:10.1371/journal.pone.0038579.t003
Table 4. Chromosomal location of the IGF2, H19 and GRB10 amplicons used in the Sequenom study.
name amplicon chromosome start* end* size (bp)
theoretical number of
CpGs per amplicon
effective number of GpCs studied via
the Sequenom EpiTYPER
IGF2 11 2161350 2161846 496 45 30
H19_4 11 2021131 2021590 459 19 15
H19_14 11 2022413 2022822 409 17 10
GRB10 7 50850662 50851041 379 20 18
*Nucleotide positions according to the February 2009 human reference sequence (GRCh37/hg19) produced by the International Human Genome Sequencing
Consortium.
doi:10.1371/journal.pone.0038579.t004
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was available for further analysis. When platelet aggregation was
induced with collagen in the patients, after preincubation with
either prostaglandin E1 (Prostin) or a stable prostacyclin analogue
(Iloprost), significantly higher concentrations of both Gs agonists
were required to achieve the 50% inhibition of platelet aggrega-
tion (IC50), as compared to the healthy controls. This platelet
aggregation-inhibition Gs test was performed in 24 healthy
controls and we compared their mean IC50 values for patients.
Genetic analysis of GNAS
Since our patients with an AHO-like phenotype were clinically
diagnosed as having PPHP or POH (only for patient 5) and had
platelet Gs hypofunction, GNAS screening for inactivation
mutations was performed using leukocyte gDNA for sequencing
the PCR amplified 13 exons, including exon/intron boundaries.
No GNAS coding mutations were found in any of the patients. All
patients were heterozygous for at least one of the studied GNAS
region SNPs, excluding small chromosomal deletions within the
GNAS cluster (Table S1). In addition, patients 5 to 17 were
previously studied for copy number variants within the GNAS
locus or its surrounding region and found to be negative [44].
Study of GNAS methylation
GNAS methylation was screened for the three amplicons NESP,
XL and ExonA/B using the Sequenom EpiTYPER as we
previously optimized for PHP-Ib and PHP-Ia cases [19]. We
could observe a significant hypermethylation for the XL amplicon
in patients vs. controls (3663 vs. 2963% (mean6SD); T-test,
p,0.001; Figure 1A). Interestingly, this is the opposite pattern of
the methylation defect described for PHP-Ib and PHP-Ia patients
having pronounced XL hypomethylation [19]. Overall methyla-
tion that includes all studied CpGs in the amplicons for NESP and
ExonA/B did not show any significant difference between patients
and controls (Figure 1A) though some separate patients (patient
1, 2 and 3 for NESP and patient 3 and 5 for ExonA/B) showed a
significant difference in overall methylation (Figure 2A). Howev-
er, the study of single CpGs within these amplicons showed
significant hyper- (red) or hypo- (green) methylation (Z-test,
p,0.05) for both the NESP and ExonA/B amplicons and for
almost all patients (Figure 2A). Based on the analysis of the single
CpGs in NESP and ExonA/B (not for XL), some patients seemed
to cluster in subgroups but these clusters did not correlate further
with the clinical severity of AHO phenotype.
Study of XLalphaS and Gsalpha expression in platelets
To evaluate whether the XL hypermethylation would be
associated with decreased XLalphaS expression, immunoblot
analysis was performed using platelet extracts as we previously
also did for a PHP-Ib patient with XL hypomethylation and
increased XLalphaS levels in platelets [41]. We have studied
XLalphaS and Gsalpha expression in platelets from 11 of the 17
patients and 5 healthy controls (Figure 3). While Gsalpha was not
statistically different between patients and controls, XLalphaS
showed a significant decreased expression (58632 vs. 100619,
respectively. T-test, p,0.05).
Study of IGF2 and H19 ICR1 methylation
We next studied 30 CpGs in the DMR1 of IGF2 and 25 CpGs
in the ICR1 of the H19 locus (Table 3 for their precise
chromosomal location). Surprisingly, we could observe significant
hypermethylation of the IGF2 amplicon in patients vs. controls
(20610 vs. 1467%; T-test, p,0.05; Figure 1B). The overall
CpG methylation for the H19 amplicon was not significantly
different for patients and controls (3568 vs. 3565%), though a
significant overall hypermethylation was observed for patients 2
and 4 (Figure 2B). For the methylation analysis of single CpGs
within the IGF2 amplicon, we could observe a significant
hypermethylation in 14 out of 17 PPHP patients at specific CpGs
(Figure 2B) (Z-test, p,0.05). For the H19 region also some
specific CpGs show significant differences in methylation but only
for a few patients and clustering within patients seemed not be
present. Spearman correlation between IGF2 methylation and
height of patients was not significant.
Study of SNURF methylation
The amplicon for SNURF included 18 CpGs and a significant
hypomethylation in the SNURF amplicon was found for patients
vs. controls (2366 vs. 3266%; T-test, p,0.001; Figure 1C).
Remarkably, single CpG analysis showed both significant hyper
(CpG7_8) and hypo (CpG14_16, CpG25) methylation
(Figure 2C) within the same amplicon and for almost all patients.
This dual pattern was not observed in any of the normal control
subjects. Spearman correlation between SNURF methylation and
weight of patients was not significant.
Study of GRB10 methylation
The amplicon for the GRB10 region included 18 CpGs and their
methylation did not appear to be significantly different between
patients and controls (3767 vs. 3466%; Figure 1C). Interestingly,
the overall methylation for patients 1 and 2 showed a significant
GRB10 hypermethylation of 56 and 50%, respectively, vs. 3566%
for controls (Z-test, p,0.05) (Figure 2C). The analysis of single
CpGs showed some significant differences for some patients with
both hyper- and hypomethylated sites (Figure 2C).
Discussion
ThehumanGNASclustercontainsthreedifferentiallymethylated
regions:NESP,XL and exonA/B[19]. Patients who develop PHP-
Ib usually present with exon A/B hypomethylation [14,45–47]. In
these familial PHP-Ib cases the latter appears to be caused by
maternallyinheriteddeletionsaffectingeithertheSTX16[39,48]or
the NESP55/NESPAS regions [40,49,50]. Broader GNAS imprint-
ing defects involving the three differentially methylated GNAS
regions arealways observedinsporadic PHP-Ib caseswith NESP55
hypermethylation versus XL and exon A/B hypomethylation
[19,46,51–53]. Recently, a similar broad epigenetic GNAS defect
was described for some PHP-Ia cases without GNAS coding
mutations [15,16,18,19]. These patients had PTH resistance but
also an AHO phenotype implicating that GNAS methylation defects
could also result in AHO features. We therefore hypothesize that
patients with an AHO-like phenotype but no endocrine abnormal-
ities and stillhaving functional Gshypofunction (often referred to as
PPHP) could present with GNAS methylation abnormalities if
coding GNAS mutations are also excluded. We studied GNAS
methylation in 16 patients with clinical diagnosis of PPHP and 1
POH patient without GNAS mutations but having platelet Gs
hypofunction and an AHO phenotype that mainly involves short
statureandbrachydactylyand/orothertypesofboneabnormalities.
GNAS methylation was quantified for the three differentially
methylated regions using the Sequenom EpiTYPER as we
previously did for PHP-Ib and PHP-Ia cases [19]. Grouped analysis
showed a significant hypermethylation for the XL amplicon in
PPHP patients versus controls (36% vs 29%; p,0.001) but overall
methylation for the NESP and ExonA/B regions was not
significantly different between patients and controls, except for
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patients3and5forExonA/B.Thesametrendforhypermethylation
inNESPandExonA/BisalsovisiblewhenanalyzingseparateCpGs
foratleastthefirst10patientswhiletheother7patientsshowaweak
trend towards hypomethylation of NESP and ExonA/B. This
peculiar methylation pattern (with hypermethylation of NESP, XL
and ExonA/B) is different from the imprinting pattern observed in
PHP-Ib and PHP-Ia patients (having NESP hyper versus XL and
Exon A/B hypomethylation).
The main defect in our patients is the significant XL
hypermethylation that could be linked to their Short for
Gestational Age (SGA) and shortness phenotype. Interestingly, it
is known that the main phenotype for XLalphaS deficient mice is
the regulation of postnatal growth with neonatal feeding problems,
leanness, inertiae and a high mortality rate [54]. Postnatally,
changes in the expression pattern of XLalphaS in different tissues
have been also characterized, as surviving mice develop into
healthy and fertile adults, which are however characterized by
leanness despite elevated food intake [55]. In addition, GNAS
deletions including the XL region have been identified in some
patients with severe pre- and/or postnatal growth retardation as
well as feeding difficulties [56,57]. We also found that the XL
hypermethylation in the patients was associated with decreased
XLalphaS protein levels in their platelets. Further studies will be
needed to evaluate whether this decreased expression of XLalphaS
could also be responsible for the platelets Gs hypofunction in these
patients. We have previously shown that XLalphas can regulate
platelet Gs activity [43,58], data that have been further supported
by studies in other cells [59–61].
Some typical AHO features are also present in patients with
other imprinting syndromes such as for the growth and
neurodevelopmental diseases Silver-Russel, Beckwith-Wiede-
mann, Prader-Willi and Angelman syndromes. In addition,
IGF2, H19 and GRB10 together with GNAS have been described
to be part of an imprinted gene network that regulate embryonic
growth and differentiation dependent on Zac-1 regulation in mice
[27]. Therefore, we have also studied the methylation of other
imprinted genes such as IGF2, H19, SNURF and GRB10.
Surprisingly, we could observe significant hypermethylation for
IGF2 (20 vs. 10%; P,0.05) and hypomethylation (23 vs. 32;
Figure 1. Overall GNAS, IGF2, H19, SNURF and GRB10 methylation in AHO-like patients. Dot plot representation of overall methylation
values (averages expressed as % of methylation) for NESP, XL, Exon A/B (A), IGF2, H19 (B), SNURF and GRB10 (C) in AHO-like patients (indicated as
‘PPHP’) vs. the control population (indicated as ‘crls’). Individuals with significant hyper- or hypomethylation (patients 1 to 5) in the NESP, Exon A/B,
H19 and GRB10 are indicated as follow: patient 1= red, 2= green, 3= blue, 4= brown, 5= yellow. Medians are displayed as black lines. ** p,0.01
and * p,0.05, two-tailed unpaired T-test.
doi:10.1371/journal.pone.0038579.g001
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e38579Figure 2. GNAS, IGF2, H19, SNURF and GRB10 methylation at single CpG sites for AHO-like patients. Single CpG site methylation values
rapresentations for all patients studied via Sequenom EpiTYPER mass-array for NESP, XL, exon A/B (A), IGF2, H19 (B), SNURF and GRB10 (C) amplicons.
% of methylation are reported as mean of three replicates from at least two separate plates and two independent DNA bisulphite treatment. White
include the normal methylation values that are within the mean +/2 SD value of the indicated number of normal controls. Values that are
significantly hyper- or hypomethylated are depicted as red or green diagonal striped rectangles, respectively (Z-test, p,0.05). Red or green rectangles
indicate methylation values that are outside the SD values but are not yet significant, indicative for a trend towards hyper or hypomethylation,
respectively. Grey rectangles are CpG values that failed in the analysis. The mean (AVG) and Standard Deviation (SD) for each CpG in the controls are
shown in the last rows. The last column in white shows the overall degree of methylation for the complete amplicon for each patient and the mean
and SD for the controls. * Z-test, p,0.05.
doi:10.1371/journal.pone.0038579.g002
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differences between patients and controls. The physiological
relevance of these findings in relation to the clinical phenotypes
remains to be studied. However, some other groups already
reported so-called multilocus methylation abnormalities (e.g. for
Beckwith-Wiedemann syndrome [62] and Silver-Russel syndrome
[63,64]). In all these reports somatic mosaicism has been proposed
to explain the patients epigenotypes as result of a post-zygotic error
of imprint setting. Interestingly, a similar overall methylation
defect has been recently described in patients with growth and
development problems [65–67].
Mutations in a trans-acting factor involved in establishing or
maintaining methylation at multiple chromosomal loci however
could also explain the presence of such overall methylation
abnormalities. The latter hypothesis has been demonstrated in the
Beckwith-Wiedemann syndrome [68], transient neonatal diabetes
[69] and the Immunodeficiency-Centromeric instability-Facial
anomalies (ICF) syndrome [70]. A similar mechanism has also
been recently postulated to exists for PHPIb cases [71] but this
remain to be proven. The methylation changes observed in our
patients seem to affect mainly maternally methylated regions as
XL, IGF2 and SNURF are paternally expressed genes (see
Figures S1, S2, S3). In conclusion we studied GNAS, IGF2, H19,
SNURF and GRB10 methylation in patients with and AHO-like
phenotype and Gs hypofunction but no GNAS coding mutations.
We could broaden the spectrum of (epi)genetic defects associated
with an AHO phenotype by identifying an epigenetic defect in
XL, IGF2 and SNURF in 16 PPHP patients and 1 POH case.
More studies on multiple imprinting control regions in more
PPHP patients are warranted to further investigate the combina-
tion of epigenetic defects in relation to phenotypes.
Supporting Information
Figure S1 GNAS schematic representation of genomic
regions studied via Sequenom EpiTYPER. GNAS sche-
matic representation of genomic regions studied via Sequenom
EpiTYPER. Features of the paternal and the maternal allele are
shown above and below the line, respectively. The arrows show
initiation and direction of transcription. Paternal and maternal
transcripts are highlighted in blue and pink, respectively. The first
exons of the protein coding transcripts are shown as black boxes
and the first exons of the noncoding transcripts (Nespas and exon
A/B) are shown as gray boxes. Differentially methylated regions
(DMRs) are shown by + symbols (indication of methylation). For
each amplicon reported in the black frames CpG sites are
underlined, CpGs studied via Sequenom are additionally depicted
in italic and bold. Red dinucleotides refer to SNPs analysed in the
same regions. The figure is not to scale. Adapted from Izzi et al.
Curr Mol Med 2012.
(TIF)
Figure S2 IGF2/H19 schematic representation of geno-
mic regions studied via Sequenom EpiTYPER. Features of
the paternal and the maternal allele are shown above and below
the line, respectively. The arrows show initiation and direction of
transcription. Paternal IGF2 transcript is highlighted in blue. The
first exons of the protein coding transcripts are shown as black
boxes. Differentially methylated regions (DMRs) are shown by +
symbols (indication of methylation). For each amplicon reported in
the black frames CpG sites are underlined, CpGs studied via
Sequenom are additionally depicted in italic and bold. Red
dinucleotides refer to SNPs analysed in the same regions. The
figure is not to scale. Adapted from Jeong et al. Nature Genetics
(2004) 36, 1036–1037.
(TIF)
Figure S3 SNURF (A) and GRB10 (B) schematic repre-
sentation of genomic regions studied via Sequenom
EpiTYPER. Features of the paternal and the maternal allele are
shown above and below the line, respectively. The arrows show
initiation and direction of transcription. Paternal SNURF
transcript is highlighted in blue. The first exons of the protein
coding transcripts are shown as black boxes. Differentially
methylated regions (DMRs) are shown by + symbols (indication
of methylation). For each amplicon reported in the black frames
CpG sites are underlined, CpGs studied via Sequenom are
additionally depicted in italic and bold. Red dinucleotides refer to
SNPs analysed in the same regions. The figure is not to scale. B
adapted from Hikichi et al. Nucleic Acids Research (2003) 31 (5):
1398–1406.
(TIF)
Figure 3. XLalphaS and Gsalpha expression in platelets from
AHO-like patients. XLalphaS, CAP1 and Gsalpha expression in AHO-
like platelets. A. Immunoblot analysis of XLalphas, CAP1 and Gsalpha
protein in platelet lysates from XL hypermethylated AHO-like patients
12, 13, 10, 14, 15, 16 and 3 controls and B. correspondent densitometric
scanning of XLalphaS protein in platelet lysates from AHO-like patients
with XL hypermethylation (patients 6 to 16) and 5 controls (Controls).
Results are expressed as percentage of controls (taken as 100%). Mean
as well as SD are depicted as black horizontal and vertical lines,
respectively. *, p value,0.05, two-tailed unpaired T-test.
doi:10.1371/journal.pone.0038579.g003
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